TY - JOUR
T1 - Gallium-68-somatostatin receptor PET/CT parameters as potential prognosticators for clinical time to progression after peptide receptor radionuclide therapy: a cohort study
AU - Ebbers, Sander C.
AU - Heimgartner, Muriel
AU - Barentsz, Maarten W.
AU - van Leeuwaarde, Rachel S.
AU - van Treijen, Mark J. C.
AU - Lam, Marnix M. E. G.
AU - Braat, Arthur J. A. T.
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12/9
Y1 - 2021/12/9
N2 - Background: Early [
68Ga]Ga-DOTA-TOC PET/CT imaging after peptide receptor radionuclide therapy (PRRT) in neuroendocrine neoplasm patients is often used as a prognosticator for survival, but lacks validity. This study investigates the prognostic value of changes in PET parameters after PRRT. Methods: Baseline and follow-up [
68Ga]Ga-DOTA-TOC PET/CT scans of all patients treated with PRRT were delineated automatically. Total lesion somatostatin receptor expression (TL-SSTR) and somatostatin receptor expressing tumor volume (SSTR-TV) were used as covariates in Cox proportional hazard models to predict time-to-new treatment. Results: In twenty patients, median time-to-new treatment was 19.3 months (range [3.8; 36.2]). Absolute and percentual changes in both PET parameters were not associated with time-to-new treatment. A significant relation between independent baseline and follow-up SSTR-TV and follow-up TL-SSTR, and time-to-new treatment was identified. Conclusions: Automatically derived [
68Ga]Ga-DOTA-TOC PET/CT parameters are easy to acquire and may be of prognostic value after completing PRRT. Acquiring SSTR-TV or TL-SSTR parameters at baseline and during follow-up can be of value in identifying a patient’s prognosis.
AB - Background: Early [
68Ga]Ga-DOTA-TOC PET/CT imaging after peptide receptor radionuclide therapy (PRRT) in neuroendocrine neoplasm patients is often used as a prognosticator for survival, but lacks validity. This study investigates the prognostic value of changes in PET parameters after PRRT. Methods: Baseline and follow-up [
68Ga]Ga-DOTA-TOC PET/CT scans of all patients treated with PRRT were delineated automatically. Total lesion somatostatin receptor expression (TL-SSTR) and somatostatin receptor expressing tumor volume (SSTR-TV) were used as covariates in Cox proportional hazard models to predict time-to-new treatment. Results: In twenty patients, median time-to-new treatment was 19.3 months (range [3.8; 36.2]). Absolute and percentual changes in both PET parameters were not associated with time-to-new treatment. A significant relation between independent baseline and follow-up SSTR-TV and follow-up TL-SSTR, and time-to-new treatment was identified. Conclusions: Automatically derived [
68Ga]Ga-DOTA-TOC PET/CT parameters are easy to acquire and may be of prognostic value after completing PRRT. Acquiring SSTR-TV or TL-SSTR parameters at baseline and during follow-up can be of value in identifying a patient’s prognosis.
KW - CT
KW - PET-based response
KW - PRRT
KW - Progression-free survival
KW - Time-to-new treatment
KW - [ Ga]Ga-DOTA-TOC PET/CT
KW - [Ga-68]Ga-DOTA-TOC PET
UR - https://www.scopus.com/pages/publications/85120966502
U2 - 10.1186/s41824-021-00116-z
DO - 10.1186/s41824-021-00116-z
M3 - Article
C2 - 34881405
VL - 5
SP - 1
EP - 11
JO - European journal of hybrid imaging
JF - European journal of hybrid imaging
IS - 1
M1 - 22
ER -